Pathological gambling in Parkinson's disease. A comprehensive review

Parkinsonism and Related Disorders

Volumn 19, Issue 7, 2013, Pages 645-653

  Santangelo, Gabriella ^a,b   Barone, Paolo ^c   Trojano, Luigi ^a   Vitale, Carmine ^b,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Institute for Diagnosis and Care Hermitage Capodimonte   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Cognitive functions; Impulse Control Disorders; Parkinson's disease; Pathological gambling

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MOOD STABILIZER; NALTREXONE; PRAMIPEXOLE; TOPIRAMATE; ZONISAMIDE;

BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; DECISION MAKING; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMPULSE CONTROL DISORDER; NEUROANATOMY; NONHUMAN; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WITHDRAWAL SYNDROME;

COGNITION DISORDERS; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; GAMBLING; HUMANS; PARKINSON DISEASE;

EID: 84878259161     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.02.007     Document Type: Review

References (157)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, text rev, DC, Washington. 4th ed.
2. Petry N.M., Armentano C. Prevalence, assessment, and treatment of pathological gambling: a review. Psychiatr Serv 1999, 50:1021-1027.
3. Holden C. 'Behavioral' addictions: do they exist?. Science 2001, 294:980-982.
4. Goudriaan A.E., Oosterlaan J., de Beurs E., Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 2004, 28:123-141.
5. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002, 159:1642-1652.
6. Jentsch J.D., Taylor J.R. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 1999, 146:373-390.
7. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
8. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006, 66:1750-1752.
9. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonists use with impulse control disorders in Parkinson's disease. Arch Neurol 2006, 63:969-973.
10. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., Bonfà F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006, 21:2068-2072.
11. Crockford D., Quickfall J., Currie S., Furtado S., Suchowersky O., El-Guebaly N. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud 2008, 24:411-422.
12. Lu C., Bharmal A., Suchowersky O. Gambling and Parkinson's disease. Arch Neurol 2006, 63:298.
13. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006, 21:2206-2208.
14. Chiang H.L., Huang Y.S., Chen S.T., Wu Y.R. Are there ethnic differences in impulsive/compulsive behaviors in Parkinson's disease?. Eur J Neurol 2012, 19:494-500.
15. Fan W., Ding H., Ma J., Chan P. Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci Lett 2009, 465:6-9.
16. Auyeung M., Tsoi T.H., Tang W.K., Cheung C.M., Lee C.N., Li R., et al. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord 2011, 17:635-637.
17. Lee J.Y., Kim J.M., Kim J.W., Cho J., Lee W.Y., Kim H.J., et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010, 16:202-207.
18. Perez-Lloret S., Rey M.V., Fabre N., Ory F., Spampinato U., Montastruc J.L., et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. Eur J Clin Pharmacol 2012, 68:857-865.
19. Djamshidian A., Cardoso F., Grosset D., Bowden-Jones H., Lees A.J. Pathological gambling in Parkinson's disease-a review of the literature. Mov Disord 2011, 26:1976-1984.
20. Weintraub D., Hoops S., Shea J.A., Lyons K.E., Pahwa R., Driver-Dunckley E.D., et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009, 24:1461-1467.
21. Cabrini S., Baratti M., Bonfà F., Cabri G., Uber E., Avanzi M. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci 2009, 30(4):307-313.
22. Papay K., Mamikonyan E., Siderowf A.D., Duda J.E., Lyons K.E., Pahwa R., et al. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat Disord 2011, 17:153-155.
23. Lim S.Y., Tan Z.K., Ngam P.I., Lor T.L., Mohamed H., Schee J.P., et al. Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP. Parkinsonism Relat Disord 2011, 17:761-764.
24. Antonini A., Siri C., Santangelo G., Cilia R., Poletti M., Canesi M., et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord 2011, 26:464-468.
25. Weintraub D., Papay K., Siderowf A., for the Parkinson's Progression Markers Initiative Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013, 80:176-180.
26. Kim S.W., Grant J.E., Eckert E.D., Faris P.L., Hartman B.K. Pathological gambling and mood disorders: clinical associations and treatment implications. J Affect Disord 2006, 92:109-116.
27. Shaffer H.J., Martin R. Disordered gambling: etiology, trajectory, and clinical considerations. Annu Rev Clin Psychol 2011, 7:483-510.
28. Lim S.Y., Evans A.H., Miyasaki J.M. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008, 1142:85-107.
29. Dagher A., Robbins T.W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009, 61:502-510.
30. Kim S.W., Grant J.E. Personality dimensions in pathological gambling disorder and obsessive-compulsive disorder. Psychiatry Res 2001, 104:205-212.
31. Grant J.E., Kim S.W. Comorbidity of impulse control disorders in pathological gamblers. Acta Psychiatr Scand 2003, 108:203-207.
32. Black D.W., Moyer T. Clinical features and psychiatric comorbidity of subjects with pathological gambling behavior. Psychiatr Serv 1998, 49:1434-1439.
33. Specker S.M., Carlson G.A., Christenson G.A., Marcotte M. Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry 1995, 7:175-179.
34. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2009, 64:S93-S100.
35. Weintraub D., Sohr M., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010, 68:963-968.
36. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007, 64:1089-1096.
37. Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S., et al. Prevalence of repetitive and reward seeking behaviors in Parkinson disease. Neurology 2006, 67:1254-1257.
38. Potenza M.N., Voon V., Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007, 3(12):664-672.
39. Isaias I.U., Siri C., Cilia R., De Gaspari D., Pezzoli G., Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 2008, 23:411-415.
40. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007, 22:1757-1763.
41. Bastiaens J., Dorfman B.J., Christos P.J., Nirenberg M.J. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013, 10.1002/mds.25291.
42. Voon V., Thomsen T., Miyasaki J.M., de Souza M., Shafro A., Fox S.H., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007, 64:212-216.
43. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011, 69:986-996.
44. Siri C., Cilia R., De Gaspari D., Canesi M., Meucci N., Zecchinelli A.L., et al. Cognitive status of patients with Parkinson's disease and pathological gambling. J Neurol 2010, 257:247-252.
45. Santangelo G., Vitale C., Trojano L., Verde F., Grossi D., Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 2009, 24:899-905.
46. Rossi M., Gerschcovich E.R., de Achaval D., Perez-Lloret S., Cerquetti D., Cammarota A., et al. Decision-making in Parkinson's disease patients with and without pathological gambling. Eur J Neurol 2010, 17:97-102.
47. Vitale C., Santangelo G., Trojano L., Verde F., Rocco M., Grossi D., et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Mov Disord 2011, 26:830-836.
48. Rugle L., Melamed L. Neuropsychological assessment of attention problems in pathological gamblers. J Nerv Ment Dis 1993, 181:107-112.
49. Regard M., Knoch D., Guting E., Landis T. Brain damage and addictive behavior: a neuropsychological and electroencephalogram investigation with pathologic gamblers. Cogn Behav Neurol 2003, 16:47-53.
50. Goudriaan A.E., Oosterlaan J., de Beurs E., Van den Brink W. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction 2006, 101:534-547.
51. Kalechstein A.D., Fong T., Rosenthal R.J., Davis A., Vanyo H., Newton T.F. Pathological gamblers demonstrate frontal lobe impairment consistent with that of methamphetamine-dependent individuals. J Neuropsychiatry Clin Neurosci 2007, 19:298-303.
52. Ledgerwood D.M., Orr E.S., Kaploun K.A., Milosevic A., Frisch G.R., Rupcich N., et al. Executive function in pathological gamblers and healthy controls. J Gambl Stud 2012, 28:89-103.
53. Marazziti D., Catena Dell'osso M., Conversano C., Consoli G., Vivarelli L., Mungai F., et al. Executive function abnormalities in pathological gamblers. Clin Pract Epidemiol Ment Health 2008, 4:7. 10.1186/1745-0179-4-7.
54. Cavedini P., Riboldi G., Keller R., D'Annucci A., Bellodi L. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry 2002, 51:334-341.
55. Paulus M.P. Neurobiology of decision-making: quo vadis?. Brain Res Cogn Brain Res 2005, 23:2-10.
56. Bechara A., Damasio A.R., Damasio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50:7-15.
57. Clark L., Bechara A., Damasio H., Aitken M.R., Sahakian B.J., Robbins T.W. Differential effects of in7ular and ventromedial prefrontal cortex lesions on risky decision making. Brain 2008, 131:1311-1322.
58. van den Heuvel O.A., der Werf Y.D., Verhoef K.M., de Wit S., Berendse H.W., Wolters ECh, et al. Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci 2010, 289:55-59.
59. Lobo D.S., Kennedy J.L. Genetic aspects of pathological gambling: a complex disorder with shared genetic vulnerabilities. Addiction 2009, 104:1454-1465.
60. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004, 23:540-545.
61. Pohjalainen T., Rinne J.O., Någren K., Lehikoinen P., Anttila K., Syvälahti E.K., et al. The A1 allele of the human D2 dopamine receptor predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998, 3:256-260.
62. Comings D.E., Rosenthal R.J., Lesieur H.R., Rugle L.J., Muhleman D., Chiu C., et al. A study of the dopamine D2 receptor in pathological gambling. Pharmacogenetics 1886, 6:223-234.
63. da Silva Lobo D.S., Vallada H.P., Knight J., Martins S.S., Tavares H., Gentil V., et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gamb Stud 2007, 23:421-433.
64. Comings D.E., Gade R., Wu S., Chiu C., Dietz G., Muhleman D., et al. Studies of the potential role of dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997, 2:44-56.
65. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
66. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996, 255:1068-1072.
67. Lim S., Ha J., Choi S.W., Kang S.G., Shin Y.C. Association study on pathological gambling and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in a Korean population. J Gambl Stud 2012, 28:481-491.
68. Van Tol H.H., Wu C.M., Guan H.C., Ohara K., Bunzow J.R., Civelli O. Multiple domain dopamine D4 receptor variants in the human population. Nature 1992, 358:149-152.
69. Benjamin J., Li L., Patterson C., Greenber B.D., Murphy D.L., Hamer D.H. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996, 12:81-84.
70. Comings D.E., Gonzalez N., Wu S., Gade R., Muhleman D., Saucier G., et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive, behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 1999, 20:358-368.
71. Perez de Castro I., Ibanez A., Torres P., Saiz-Ruiz J., Fernandez-Piqueras J. Genetic association study between pathological gambling and a functional polymorphism at the D4 receptor gene. Pharmacogenetics 1997, 7:345-348.
72. Caldú X., Vendrell P., Bartrés-Faz D., Clemente I., Bargalló N., Jurado M.A., et al. Impact of the COMT Val108/158Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 2007, 37:1437-1444.
73. Heinz A., Jones D.W., Mazzanti C., Goldman D., Ragan P., Hommer D., et al. A relationship between serotonin transporter gene and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2004, 47:643-649.
74. Perez de Castro I., Ibanez A., Saiz-Ruiz J., Fernandez-Piqueras J. Concurrent positive association between pathological gambling and functional DNA polymorphism in the MAO-A and the 5-HT transporter genes. Mol Psychiatry 2002, 7:927-928.
75. Lee J.H., Kim H.T., Hyun D.S. Possible association between serotonin transporter promoter region polymorphism and impulsivity in Koreans. Psychiatry Res 2003, 118:19-24.
76. Brewer J.A., Potenza M.N. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008, 75:63-75.
77. McFarland K., Lapish C.C., Kalivas P.W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine induced reinstatement of drug-seeking behavior. J Neurosci 2003, 23:3531-3537.
78. Lee J.Y., Lee E.K., Park S.S., Lim J.Y., Kim H.J., Kim J.S., et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009, 24:1803-1810.
79. Vallelunga A., Flaibani R., Formento-Dojot P., Biundo R., Facchini S., Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012, 18:397-399.
80. Lee J.Y., Jeon B.S., Kim H.J., Park S.S. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012, 18:76-78.
81. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992, 256:1217-1221.
82. Cormier F., Muellner J., Corvol J.C. Genetics of impulse control disorders in Parkinson's disease. J Neural Transm 2012, 10.1007/s00702-012-0934-4.
83. Koechlin E., Basso G., Pietrini P., Panzer S., Grafman J. The role of the anterior prefrontal cortex in human cognition. Nature 1999, 399:148-151.
84. Milner B., Petrides M. Behavioral effects of frontal lobe lesions in men. J Neurosci 1984, 7:403-407.
85. Passingham R.E. The frontal lobes and voluntary action 1993, Oxford University Press, Oxford.
86. Shallice T., Burgess P.W. Deficits in strategy application following frontal lobe damage in man. Brain 1991, 114:727-741.
87. Stuss D.T. Biological and psychological development of executive functions. Brain Cogn 1992, 20:8-23.
88. Compton R.J. The interface between emotion and attention: a review of evidence from psychology and neuroscience. Behav Cogn Neurosci Rev 2003, 2:115-129.
89. Malloy P., Bihrle A., Duffy J., Cimino C. The orbitomedial frontal syndrome. Arch Clin Neuropsychol 1993, 8:185-201.
90. Potenza M.N., Leung H.C., Blumberg H.P., Peterson B.S., Fulbright R.K., Lacadie C.M., et al. An fMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003, 160:1990-1994.
91. Potenza M.N., Steinberg M.A., Skudlarski P., Fulbright R.K., Lacadie C.M., Wilber M.K., et al. Gambling urges in pathological gambling: a functional Magnetic Resonance Imaging study. Arch Gen Psychiatry 2003, 60:828-836.
92. Reuter J., Raedler T., Rose M., Hand I., Glascher J., Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005, 8:147-148.
93. de Greck M., Enzi B., Prosch U., Gantman A., Tempelmann C., Northoff G. Decreased neuronal activity in reward circuitry of pathological gamblers during processing of personal relevant stimuli. Hum Brain Mapp 2010, 31:1802-1812.
94. van Holst R.J., van Holstein M., van den Brink W., Veltman D.J., Goudriaan A.E. Response inhibition during cue reactivity in problem gamblers: an fMRI study. PLoS One 2012, 7:e30909.
95. Balodis I.M., Kober H., Worhunsky P.D., Stevens M.C., Pearlson G.D., Potenza M.N. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry 2012, 71:749-757.
96. Power Y., Goodyear B., Crockford D. Neural correlates of pathological gamblers preference for immediate rewards during the Iowa gambling task: an fMRI study. J Gambl Stud 2011, 10.1007/s10899-011-9278-5.
97. Bault N., Joffily M., Rustichini A., Coricelli G. Medial prefrontal cortex and striatum mediate the influence of social comparison on the decision process. Proc Natl Acad Sci U S A 2011, 108:16044-16049.
98. Schonberg T., Fox C.R., Mumford J.A., Congdon E., Trepel C., Poldrack R.A. Decreasing ventromedial prefrontal cortex activity during sequential risk-taking: an FMRI investigation of the balloon analog risk task. Front Neurosci 2012, 6:80.
99. Balodis I.M., Lacadie C.M., Potenza M.N. A preliminary study of the neural correlates of the intensities of self-reported gambling urges and emotions in men with pathological gambling. J Gambl Stud 2011, 10.1007/s10899-011-9259-8.
100. Kassubek J., Abler B., Pinkhardt E.H. Neural reward processing under dopamine agonists: imaging. J Neurol Sci 2011, 310:36-39. 89.
101. Cilia R., Siri C., Marotta G., Isaias I.U., De Gaspari D., Canesi M., et al. Functional abnormalities underlying pathological gambling in Parkinson's disease. Arch Neurol 2008, 65:1604-1611.
102. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., et al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
103. Cilia R., Cho S.S., van Eimeren T., Marotta G., Siri C., Ko J.H., et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord 2011, 26:225-233.
104. Joutsa J., Martikainen K., Niemelä S., Johansson J., Forsback S., Rinne J.O., et al. Increased medial orbitofrontal [(18) F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord 2012, 27:778-782.
105. Ray N., Miyasaki J.M., Zurowski M., Ko J.H., Cho S.S., Pellecchia G., et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis 2012, 48:519-525.
106. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988, 318:876-880.
107. Swainson R., Rogers R.D., Sahakian B.J., Summers B.A., Polkey C.E., Robbins T.W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
108. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001, 11:1136-1143.
109. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41:1431-1441.
110. Cools R., Lewis S.J., Clark L., Barker R.A., Robbins T.W. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007, 32:180-189.
111. van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
112. Pontone G., Williams J.R., Basset S.S., Marsh L. Clinical features associated with impulse control disorders in Parkinson's disease. Neurology 2006, 67:1258-1261.
113. Paulson P.E., Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 1995, 19:56-65.
114. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997, 94:3363-3367.
115. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006, 5:25-43.
116. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999, 400:371-375.
117. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 1996, 93:1945-1949.
118. Singh A., Kandimala G., Dewey R.B., O'Suilleabhain P. Risk factors for pathological gambling and other compulsion among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007, 14:1178-1181.
119. Mamikonyan E., Siderowf A.D., Duda J.E., Potenza M.N., Horn S., Stern M.B., et al. Long term follow up of impulse control disorders in Parkinson's disease. Mov Disord 2008, 23:75-80.
120. Kimber T.E., Thompson P.D., Kiley M.A. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonists therapy in Parkinson's disease. J Clin Neurosci 2008, 15:205-208.
121. Szarfman A., Doraiswamy P.M., Tonning J.M., Levine J.G. Association between pathological gambling and parkinsonian therapy is detected in the food and drug administration adverse event database. Arch Neurol 2006, 63:299-300.
122. Avanzi M., Uber E., Bonfà F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 2004, 25:98-101.
123. Goodwin F.K. Psychiatric side effects of levodopa in man. JAMA 1971, 218:1915-1920.
124. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonists therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005, 11:381-386.
125. Tyne H.L., Medley G., Ghadiali E., Steiger M.J. Gambling in Parkinson's disease. Mov Disord 2004, 19(Suppl. 9):S195.
126. Vitale C., Santangelo G., Erro R., Errico D., Manganelli F., Improta I., et al. Impulse control disorders induced by Rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2013, PII: S1353-8020(12)00441-5. doi:10.1016/j.parkreldis.2012.11.008.
127. Moum S.J., Price C.C., Limotai N., Oyama G., Ward H., Jacobson C., et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012, 7:e29768.
128. Ardouin C., Voon V., Worbe Y., Abouazar N., Czernecki V., Hosseini H., et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006, 21:1941-1946.
129. Witjas T., Baunez C., Henry J.M., Delfini M., Regis J., Cherif A.A., et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005, 20:1052-1055.
130. Houeto J.L., Mesnage V., Mallet L., Pillon B., Gargiulo M., du Moncel S.T., et al. Behavioral disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002, 72:701-707.
131. Smeding H.M., Goudriaan A.E., Foncke E.M., Schuurman P.R., Speelman J.D., Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:517-519.
132. Voon V., Moro E., Saint-Cyr J.A., Lozano A.M., Lang A.E. Psychiatric symptoms following surgery for Parkinson's disease with an emphasis on subthalamic nucleus. Adv Neurol 2005, 96:130-147.
133. Voon V., Krack P., Lang A.E., Lozano A.M., Dujardin K., Schüpbach M., et al. A multicenter study on suicide outcomes following subthalamic nucleus stimulation for Parkinson's disease. Brain 2008, 131:2720-2728.
134. Frank M.J., Samanta J., Moustafa A.A., Sherman S.J. Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinson's disease. Science 2007, 318:1309-1312.
135. Alberts J.L., Voelcker-Rehage C., Hallahan K., Vitek M., Bamzai R., Vitek J.L. Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 2008, 131:3348-3360.
136. Mallet L., Schüpbach M., N'Diaye K., Remy P., Bardinet E., Czernecki V., et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007, 104:10661-10665.
137. Nirenberg M.J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006, 21:524-529.
138. Sohtaoĝlu M., Demiray D.Y., Kenangil G., Ozekmekçi S., Erginöz E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2010, 16:334-337.
139. Solla P., Cannas A., Marrosu M.G., Marrosu F. Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. J Neurol 2012, 259:2752-2754.
140. Giugni J.C., Tschopp L., Escalante V., Micheli F. Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol 2012, 35:49-50.
141. Vitale C., Santangelo G., Verde F., Amboni M., Sorrentino G., Grossi D., et al. Exercise dependence induced by pramipexole in Parkinson's disease-a case report. Mov Disord 2010, 25:2893-2894.
142. Vitale C., Trojano L., Barone P., Errico D., Agosti V., Sorrentino G., et al. Compulsive drumming induced by dopamine agonists treatment in Parkinson's disease: another aspect of punding. Behav Neurol 2012, 10.3233/BEN-129024.
143. Stamey W., Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008, 14(2):89-99.
144. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010, 67:58-63.
145. Driver-Dunckley E., Samanta J., Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003, 61:422-423.
146. Sevincok L., Akoglu A., Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 2007, 27:107-108.
147. Seedat S., Kesler S., Niehaus D.J., Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000, 11:185-186.
148. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004, 19:433-437.
149. Grant J.E., Potenza M.N. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004, 16:27-34.
150. Bermejo P.E. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:448-449.
151. Bermejo P.E., Ruiz-Huete C., Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010, 257:1682-1685.
152. Thomas A., Bonanni L., Gambi F., Di Iorio A., Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010, 68:400-404.
153. Lee J.Y., Kim H.J., Jeon B.S. Is pathological gambling in Parkinson's disease reduced by amantadine?. Ann Neurol 2011, 69:213-214.
154. Walsh R.A., Lang A.E. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 2012, 27:326.
155. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26(S3):S42-S80.
156. Bosco D., Plastino M., Colica C., Bosco F., Arianna S., Vecchio A., et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 2012, 35:118-120.
157. Ikemoto S., Glazier B.S., Murphy J.M., McBride W.J. Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci 1997, 17:8580-8587.